Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$24.56
-3.1%
$24.77
$22.64
$53.96
$1.19B0.77491,996 shs672,732 shs
Azenta, Inc. stock logo
AZTA
Azenta
$29.64
-1.0%
$27.53
$23.91
$63.58
$1.37B1.62702,426 shs901,287 shs
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
$5.32
-2.4%
$5.22
$3.97
$28.41
$493.23M1.591.89 million shs4.33 million shs
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$50.20
-0.5%
$47.95
$28.72
$58.38
$4.00B0.51875,469 shs3.44 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
-3.08%-4.88%+1.66%-13.18%-38.68%
Azenta, Inc. stock logo
AZTA
Azenta
-1.00%-3.14%+7.86%-20.81%-47.10%
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
-2.39%-9.98%+26.67%-39.34%-77.21%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-0.46%-2.07%+8.63%-12.15%+40.93%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
4.2255 of 5 stars
3.11.00.03.72.74.21.3
Azenta, Inc. stock logo
AZTA
Azenta
3.2208 of 5 stars
3.31.00.00.02.62.52.5
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
3.8902 of 5 stars
3.91.00.00.02.80.83.8
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
4.6336 of 5 stars
4.34.00.04.42.00.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
2.25
Hold$32.3331.65% Upside
Azenta, Inc. stock logo
AZTA
Azenta
2.50
Moderate Buy$50.6770.94% Upside
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
1.86
Reduce$15.00181.95% Upside
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
2.67
Moderate Buy$65.0029.48% Upside

Current Analyst Ratings Breakdown

Latest AZTA, PTCT, FTRE, and AMPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$80.00
5/27/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$68.00 ➝ $74.00
5/22/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
5/14/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/14/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$10.00 ➝ $8.00
5/14/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$7.00 ➝ $5.00
5/13/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$6.00 ➝ $5.00
5/12/2025
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral$45.00 ➝ $30.00
5/9/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$55.00 ➝ $68.00
5/8/2025
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$40.00 ➝ $35.00
5/8/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.00
(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$731.97M1.58$4.85 per share5.06$15.23 per share1.61
Azenta, Inc. stock logo
AZTA
Azenta
$656.32M2.07$4.50 per share6.58$36.16 per share0.82
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
$2.70B0.18$1.53 per share3.47$15.19 per share0.35
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$806.78M4.93N/AN/A($14.24) per share-3.53
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$159.52M$2.768.907.476.6019.38%22.20%10.40%8/6/2025 (Estimated)
Azenta, Inc. stock logo
AZTA
Azenta
-$164.17M-$1.39N/A32.22N/A-10.31%1.30%1.10%8/5/2025 (Estimated)
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
-$328.50M-$8.79N/A4.160.37-29.43%2.84%1.06%8/11/2025 (Estimated)
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-$363.30M$6.517.71N/AN/A33.56%-78.56%32.11%8/6/2025 (Estimated)

Latest AZTA, PTCT, FTRE, and AMPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
-$0.07$0.02+$0.09-$6.25$609.63 million$651.30 million
5/7/2025Q2 2025
Azenta, Inc. stock logo
AZTA
Azenta
$0.09$0.05-$0.04-$0.89$140.87 millionN/A
5/6/2025Q1 2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$0.85$10.04+$9.19N/A$437.16 million$1.18 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
N/AN/AN/AN/AN/A
Azenta, Inc. stock logo
AZTA
Azenta
N/AN/AN/AN/AN/A
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
N/AN/AN/AN/AN/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
0.80
2.95
2.02
Azenta, Inc. stock logo
AZTA
Azenta
N/A
3.22
2.84
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
1.22
0.97
0.97
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
3.89
3.85

Institutional Ownership

CompanyInstitutional Ownership
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
65.09%
Azenta, Inc. stock logo
AZTA
Azenta
99.08%
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
N/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
27.50%
Azenta, Inc. stock logo
AZTA
Azenta
10.62%
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
0.38%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
5.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
2,02847.14 million34.18 millionOptionable
Azenta, Inc. stock logo
AZTA
Azenta
3,30045.78 million40.92 millionOptionable
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
15,50090.50 million90.16 millionOptionable
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
1,41079.26 million74.90 millionOptionable

Recent News About These Companies

Analysts Issue Forecasts for PTCT FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amphastar Pharmaceuticals stock logo

Amphastar Pharmaceuticals NASDAQ:AMPH

$24.56 -0.78 (-3.08%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$24.56 0.00 (0.00%)
As of 06/20/2025 06:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Azenta stock logo

Azenta NASDAQ:AZTA

$29.64 -0.30 (-1.00%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$29.65 +0.01 (+0.03%)
As of 06/20/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

Fortrea stock logo

Fortrea NASDAQ:FTRE

$5.32 -0.13 (-2.39%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$5.48 +0.16 (+3.01%)
As of 06/20/2025 06:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

PTC Therapeutics stock logo

PTC Therapeutics NASDAQ:PTCT

$50.20 -0.23 (-0.46%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$50.20 0.00 (0.00%)
As of 06/20/2025 06:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.